Description
FM-A13 is a selective inhibitor of Bruton’s tyrosine kinase (BTK) – IC₅₀’s = 2.5 µM (recombinant BTK) and 17.2 µM (human BTK). It has also been shown to inhibit Polo-like kinase (PLK) (IC₅₀ = 61 µM for human PLK3). It displays no activity (concentrations up to 278 µM) at JAK1, JAK3, HCK, EGFRK and IRK2 or CDK1-3, CHK1, IKK, MAPK1, SAPK2a and ten tyrosine kinases.
FM-A13 is a selective inhibitor of Bruton’s tyrosine kinase (BTK) – IC₅₀’s = 2.5 µM (recombinant BTK) and 17.2 µM (human BTK).
Alternate Name/Synonyms: (2Z) -2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide
Appearance: White solid
Formulation: N/A
CAS Number: 244240-24-2
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₁₁H₈Br2N₂O₂
Molecular Weight: 360
Cell-Permeable?: Yes
Purity: ≥98% by TLC
Solubilities: DMSO (~15 mg/ml) or EtOH (~15 mg/ml)
Handling: Protect from light and air
Country of Origin: USA
Tag Line: A BTK inhibitor
MDL Number: MFCD09878279
PubChem CID: 54676905
SMILES: CC(=C(C#N)C(=O)NC1=C(C=CC(=C1)Br)Br)O
InChi: InChI=1S/C11H8Br2N2O2/c1-6(16)8(5-14)11(17)15-10-4-7(12)2-3-9(10)13/h2-4,16H,1H3,(H,15,17)/b8-6-
InChi Key: SVTDVJQAJIFG-VURMDHGXSA-N
Additional Information
Storage Condition: |
-20 ̊C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |